EdwardAllenNeuweltMD

Neurosurgery • Portland, OR

Professor of Neurological Surgery, Oregon Hlth & Sci Univ

Join to view full profile

Are you Dr. Neuwelt?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 39 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
3181 Sw Sam Jackson Park Rd
L603
Portland, OR 97239
Phone+1 503-494-5626

Summary

Dr. Edward Neuwelt, MD is a neurosurgeon in Portland, Oregon. He is currently licensed to practice medicine in Oregon, Maryland, and Colorado. He is affiliated with OHSU Hospital and Portland HCS.

Education & Training

University of Texas Southwestern Medical CenterResidency, Neurological Surgery, 1976 - 1978
University of MarylandResidency, Internal Medicine, 1974 - 1975
University of Texas Southwestern Medical CenterResidency, Neurological Surgery, 1973 - 1974
University of Texas Southwestern Medical Center/Parkland Memorial HospitalInternship, Transitional Year, 1972 - 1973
University of Colorado School of Medicine Anschutz Medical CampusClass of 1972

Certifications & Licensure

OR State Medical License 1981 - 2021
TX State Medical License 1973 - 1987
MD State Medical License 1975 - 1981
CO State Medical License 1973 - 1977
American Board of Neurological Surgery Neurological Surgery

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Portland Monthly Magazine Castle Connolly, 2011
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Fellow (FAANS) American Association of Neurological Surgeons
Join now to see all

Clinical Trials

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen Start of enrollment: 2003 Jan 01
Terminated
Phase 2
Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma Start of enrollment: 2000 Jan 01
Completed
Phase 2
Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma Start of enrollment: 2000 Jan 01
Completed
Phase 2
Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors Start of enrollment: 2003 Mar 07
Active, not recruiting
Phase 2
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases Start of enrollment: 2004 Jun 04
Completed
Not Applicable
Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors Start of enrollment: 2004 Dec 01
Terminated
Phase 1
Melphalan With BBBD in Treating Patients With Brain Malignancies Start of enrollment: 1998 May 01
Terminated
Phase 1
Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Start of enrollment: 2005 Oct 14
Active, not recruiting
Phase 1, Phase 2
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors Start of enrollment: 2005 Sep 15
Completed
Phase 1, Phase 2
BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain Start of enrollment: 2013 Oct 01
Withdrawn
Phase 1, Phase 2
Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure Start of enrollment: 2007 Nov 01
Terminated
Phase 1
Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors Start of enrollment: 2006 Nov 16
Terminated
Phase 2
Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation Start of enrollment: 2000 Aug 01
Terminated
Phase 2
MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation Start of enrollment: 2004 Jul 01
Terminated
Phase 2
MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy Start of enrollment: 2006 Dec 01
Completed
Not Applicable
Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors Start of enrollment: 2008 Jul 01
Terminated
Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy Start of enrollment: 2008 Oct 01
Terminated
Phase 1
DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors Start of enrollment: 2009 Aug 01
Completed
Early Phase 1
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors Start of enrollment: 2009 Jul 09
Active, not recruiting
Phase 1, Phase 2
N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer Start of enrollment: 2010 Jun 01
Withdrawn
Phase 1
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System Start of enrollment: 2017 Oct 06
Recruiting
Phase 2
Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases Start of enrollment: 2017 Nov 03
Terminated
Phase 2
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma Start of enrollment: 2017 Dec 20
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Comparison of dynamic susceptibility contrast (DSC) using gadolinium and iron-based contrast agents in high-grade glioma at high-field MRI.
Doonyaporn Wongsawaeng, Daniel Schwartz, Xin Li, Leslie L Muldoon, Jared Stoller
The Neuroradiology Journal. 2024-08-01
Deciphering spatially distinct immune microenvironments in glioblastoma using ferumoxytol and gadolinium-enhanced and FLAIR hyperintense MRI phenotypes.
Jared Stoller, Cymon N Kersch, Leslie L Muldoon, Prakash Ambady, Christina A Harrington
Neuro-Oncology Advances. 2023-11-08
6 citations
Intravenous N-Acetylcysteine to Prevent Cisplatin-Induced Hearing Loss in Children: A Nonrandomized Controlled Phase I Trial.
Etan Orgel, Kristin R Knight, Yueh-Yun Chi, Jemily Malvar, Teresa Rushing
Clinical Cancer Research. 2023-07-05

Press Mentions

Driven by OHSU Research, FDA Approves New Drug to Prevent Hearing Loss in Children with CancerJanuary 17th, 2023
Tough Choices: Chemo That Can Save Kids with Cancer Can Also Damage HearingSeptember 28th, 2021
OHSU School of Medicine Researchers Teach High School Students to Be ScientistsDecember 10th, 2019
Join now to see all

Grant Support

Delivery Issues In Lung Cancer CNS MetastasesVeterans Affairs2012
Opening Of The Blood-Brain Barrier To Antitumor AgentsNational Institute Of Neurological Disorders And Stroke2010–2012
The Annual Blood-Brain Barrier Consortium MeetingNational Cancer Institute2006–2012
The Annual Blood-Brain Barrier Consortium MeetingNational Institute Of Neurological Disorders And Stroke2011
Two Compartment Models To Improve Brain Tumor TherapyNational Cancer Institute2008–2011
Nanoparticle MR Imaging Of BBB Inflammation At High Tesla In CNS TumorsNational Institute Of Neurological Disorders And Stroke2007–2011
Opening Of The Blood Brain Barrier To Antitumor AgentsNational Institute Of Neurological Disorders And Stroke2002–2008
CNS Gene Delivery And Imaging In Brain Tumor TherapyNational Institute Of Neurological Disorders And Stroke2003–2007
Two Compartment Models To Improve Brain Tumor TherapyNational Institute Of Neurological Disorders And Stroke1999–2007
Ferumoxytol And TumorsNational Center For Research Resources2005
Annual Blood-Brain Barrier Consortium MeetingNational Cancer Institute2005
MR, Histologic And EM Imaging Of Intravenous Particles To Brain TumorsNational Center For Research Resources2004–2005
The Annual Blood Brain Barrier Consortium MeetingNational Cancer Institute2000–2004
CNS Gene Delivery And Efficacy In Brain Tumor TherapyNational Institute Of Neurological Disorders And Stroke1996–2001
Opening Of The Blood-Brain Barrier To Antitumor AgentsNational Cancer Institute1994–2001
Delivery Of Diagnostic And Therapeutic Mabs To CNSNational Institute Of Neurological Disorders And Stroke1995–1998
Opening The Blood-Brain Barrier To Antitumor AgentsNational Cancer Institute1993
Pathogenesis And Gene Therapy In Gm2-GangliosidosisNational Institute Of Neurological Disorders And Stroke1990–1992
Osmotic Opening Of The Blood-Brain BarrierNational Cancer Institute1988–1992
Osmotic Opening Of The BBB To Anti-Tumor AgentsNational Cancer Institute1985–1988

EdwardAllenNeuweltMD

Are you Dr. Neuwelt?

Summary

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Professional Memberships